{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:18:39Z","timestamp":1791926319547,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["50531\u20132022"],"award-info":[{"award-number":["50531\u20132022"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["KDDF-201504-01"],"award-info":[{"award-number":["KDDF-201504-01"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003704","name":"Korea Research Institute of Chemical Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020M2D9A2094153"],"award-info":[{"award-number":["NRF-2020M2D9A2094153"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008003","name":"Korea Institute of Radiological and Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejca.2022.06.031","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T05:12:43Z","timestamp":1657861963000},"page":"41-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract"],"prefix":"10.1016","volume":"173","author":[{"given":"Dong Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Ju","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Yong","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uk\u2013Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seohyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Mi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Tae","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungjin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2022.06.031_bib1","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.ejca.2022.06.031_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/ml400508g","article-title":"Tankyrase inhibitors: potential treatment of hyperproliferative diseases","volume":"5","author":"Abdel-Magid","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.ejca.2022.06.031_bib3","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1146\/annurev.cellbio.20.010403.113126","article-title":"The Wnt signaling pathway in development and disease","volume":"20","author":"Logan","year":"2004","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.ejca.2022.06.031_bib4","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1158\/1078-0432.CCR-10-1204","article-title":"Targeting Wnt signaling in colon cancer stem cells","volume":"17","author":"de Sousa","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2022.06.031_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0092-8674(00)00122-7","article-title":"Linking colorectal cancer to Wnt signaling","volume":"103","author":"Bienz","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2022.06.031_bib6","first-page":"1","article-title":"Tankyrase inhibitors as antitumor agents: a patent update (2013 - 2020)","author":"Mehta","year":"2021","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"10.1016\/j.ejca.2022.06.031_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s12276-020-0380-6","article-title":"Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond beta-catenin and the destruction complex","volume":"52","author":"Jung","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.ejca.2022.06.031_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112712","article-title":"Insights of tankyrases: a novel target for drug discovery","volume":"207","author":"Damale","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"3","key":"10.1016\/j.ejca.2022.06.031_bib9","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.celrep.2015.09.014","article-title":"Tankyrase inhibitors target YAP by stabilizing angiomotin family proteins","volume":"13","author":"Wang","year":"2015","journal-title":"Cell Rep"},{"issue":"7264","key":"10.1016\/j.ejca.2022.06.031_bib10","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nature08356","article-title":"Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling","volume":"461","author":"Huang","year":"2009","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ejca.2022.06.031_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033740","article-title":"Novel binding mode of a potent and selective tankyrase inhibitor","volume":"7","author":"Gunaydin","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ejca.2022.06.031_bib12","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1535-7163.MCT-15-0938","article-title":"The discovery and characterization of K-756, a novel wnt\/beta-catenin pathway inhibitor targeting tankyrase","volume":"15","author":"Okada-Iwasaki","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"10.1016\/j.ejca.2022.06.031_bib13","doi-asserted-by":"crossref","first-page":"28273","DOI":"10.18632\/oncotarget.8626","article-title":"The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance","volume":"7","author":"Quackenbush","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ejca.2022.06.031_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0192623315621192","article-title":"Tankyrase inhibition causes reversible intestinal toxicity in mice with a therapeutic index < 1","volume":"44","author":"Zhong","year":"2016","journal-title":"Toxicol Pathol"},{"issue":"11","key":"10.1016\/j.ejca.2022.06.031_bib15","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1158\/0008-5472.CAN-11-3336","article-title":"A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice","volume":"72","author":"Waaler","year":"2012","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2022.06.031_bib16","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1111\/cas.13805","article-title":"RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model","volume":"109","author":"Mizutani","year":"2018","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.ejca.2022.06.031_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41598-018-36447-4","article-title":"A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4\/6 inhibitors","volume":"9","author":"Menon","year":"2019","journal-title":"Sci Rep"},{"issue":"16","key":"10.1016\/j.ejca.2022.06.031_bib18","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1021\/jm400807n","article-title":"Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor","volume":"56","author":"Shultz","year":"2013","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.ejca.2022.06.031_bib19","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1158\/0008-5472.CAN-12-4562","article-title":"A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth","volume":"73","author":"Lau","year":"2013","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"10.1016\/j.ejca.2022.06.031_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijpharm.2012.08.031","article-title":"Development of novel microprecipitated bulk powder (MBP) technology for manufacturing stable amorphous formulations of poorly soluble drugs","volume":"438","author":"Shah","year":"2012","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ejca.2022.06.031_bib21","series-title":"Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof","author":"Jung","year":"2016"},{"issue":"4","key":"10.1016\/j.ejca.2022.06.031_bib22","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/1535-7163.MCT-16-0578","article-title":"APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer","volume":"16","author":"Tanaka","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.ejca.2022.06.031_bib23","article-title":"Quantitative proteomic analysis of 2D and 3D cultured colorectal cancer cells: profiling of tankyrase inhibitor XAV939-induced proteome","volume":"8","author":"Kim","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ejca.2022.06.031_bib24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/ncb2048","article-title":"Wnt activity defines colon cancer stem cells and is regulated by the microenvironment","volume":"12","author":"Vermeulen","year":"2010","journal-title":"Nat Cell Biol"},{"issue":"5","key":"10.1016\/j.ejca.2022.06.031_bib25","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.molcel.2009.11.017","article-title":"Evidence that fold-change, and not absolute level, of beta-catenin dictates Wnt signaling","volume":"36","author":"Goentoro","year":"2009","journal-title":"Mol Cell"},{"issue":"10","key":"10.1016\/j.ejca.2022.06.031_bib26","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/2159-8290.CD-19-0289","article-title":"Distinct colorectal cancer-associated APC mutations dictate response to tankyrase inhibition","volume":"9","author":"Schatoff","year":"2019","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.ejca.2022.06.031_bib27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrd4233","article-title":"Can we safely target the WNT pathway?","volume":"13","author":"Kahn","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.ejca.2022.06.031_bib28","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nri3896","article-title":"Emerging cytokine networks in colorectal cancer","volume":"15","author":"West","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"38","key":"10.1016\/j.ejca.2022.06.031_bib29","doi-asserted-by":"crossref","first-page":"41307","DOI":"10.18632\/oncotarget.5846","article-title":"E7449: a dual inhibitor of PARP1\/2 and tankyrase1\/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling","volume":"6","author":"McGonigle","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejca.2022.06.031_bib30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1158\/0008-5472.CAN-10-1282","article-title":"Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth","volume":"71","author":"Waaler","year":"2011","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2022.06.031_bib31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1078-0432.CCR-14-3081","article-title":"Tankyrase inhibition blocks wnt\/beta-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer","volume":"22","author":"Arques","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2022.06.031_bib32","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1158\/1078-0432.CCR-16-1179","article-title":"AZ1366: an inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition","volume":"23","author":"Scarborough","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2022.06.031_bib33","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: the use of in\u00a0vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.ejca.2022.06.031_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12964-021-00712-3","article-title":"Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage","volume":"19","author":"Ternet","year":"2021","journal-title":"Cell Commun Signal"},{"issue":"7","key":"10.1016\/j.ejca.2022.06.031_bib35","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1021\/acs.jmedchem.8b01888","article-title":"Discovery of novel spiroindoline derivatives as selective tankyrase inhibitors","volume":"62","author":"Shirai","year":"2019","journal-title":"J Med Chem"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:34:58Z","timestamp":1762342498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922003823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":35,"alternative-id":["S0959804922003823"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.031","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}